Author

Mattias Mandorfer

SEQUENTIAL CONSIDERATION OF VITRO SUBSTANTIALLY REDUCES THE DIAGNOSTIC AND PROGNOSTIC GREY ZONE OF THE BAVENO-VII CRITERIA FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION
SEQUENTIAL CONSIDERATION OF VITRO SUBSTANTIALLY REDUCES THE DIAGNOSTIC AND PROGNOSTIC GREY ZONE OF THE BAVENO-VII CRITERIA FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION

Mattias Mandorfer  et al.

VON WILLEBRAND FACTOR FOR OUTCOME PREDICTION WITHIN DIFFERENT CLINICAL STAGES OF ADVANCED CHRONIC LIVER DISEASE
VON WILLEBRAND FACTOR FOR OUTCOME PREDICTION WITHIN DIFFERENT CLINICAL STAGES OF ADVANCED CHRONIC LIVER DISEASE

Mattias Mandorfer  et al.

CLINICAL COURSE OF FURTHER DECOMPENSATION/MORTALITY IN PATIENTS WITH CIRRHOSIS AND ASCITES AS THE FIRST SINGLE DECOMPENSATION EVENT – AN INCEPTION COHORT STUDY
CLINICAL COURSE OF FURTHER DECOMPENSATION/MORTALITY IN PATIENTS WITH CIRRHOSIS AND ASCITES AS THE FIRST SINGLE DECOMPENSATION EVENT – AN INCEPTION COHORT STUDY

Mattias Mandorfer  et al.

THE IMPACT OF TRANSMEMBRANE 6 SUPERFAMILY 2 (TM6SF2) RS58542926 ON LIVER-RELATED EVENTS IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE
THE IMPACT OF TRANSMEMBRANE 6 SUPERFAMILY 2 (TM6SF2) RS58542926 ON LIVER-RELATED EVENTS IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE

Mattias Mandorfer  et al.

THE ALPHA-1 ANTITRYPSIN PI*Z ALLELE INDEPENDENTLY PREDICTS LIVER TRANSPLANTATION/DEATH IN ACLD PATIENTS
THE ALPHA-1 ANTITRYPSIN PI*Z ALLELE INDEPENDENTLY PREDICTS LIVER TRANSPLANTATION/DEATH IN ACLD PATIENTS

Mattias Mandorfer  et al.

FACTOR VIII/PROTEIN C RATIO INDEPENDENTLY PREDICTS LIVER-RELATED EVENTS BUT DOES NOT REFLECT THE HYPERCOAGULABLE STATE IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE
FACTOR VIII/PROTEIN C RATIO INDEPENDENTLY PREDICTS LIVER-RELATED EVENTS BUT DOES NOT REFLECT THE HYPERCOAGULABLE STATE IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE

Mattias Mandorfer  et al.

CLINICAL SIGNIFICANCE OF SUBSTANTIALLY ELEVATED VON WILLEBRAND FACTOR ANTIGEN LEVELS IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE
CLINICAL SIGNIFICANCE OF SUBSTANTIALLY ELEVATED VON WILLEBRAND FACTOR ANTIGEN LEVELS IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE

Mattias Mandorfer  et al.

A FIB-4/VITRO SEQUENCE ALLOWS FOR DIAGNOSIS OF COMPENSATED ADVANCED CHRONIC LIVER DISEASE AND RISK STRATIFICATION FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION
A FIB-4/VITRO SEQUENCE ALLOWS FOR DIAGNOSIS OF COMPENSATED ADVANCED CHRONIC LIVER DISEASE AND RISK STRATIFICATION FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION

Mattias Mandorfer  et al.

NON-INVASIVE TESTS FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AFTER HCV-CURE – INDIVIDUAL PATIENT DATA META-ANALYSIS AND VALIDATION
NON-INVASIVE TESTS FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AFTER HCV-CURE – INDIVIDUAL PATIENT DATA META-ANALYSIS AND VALIDATION

Mattias Mandorfer  et al.

PROGNOSTIC UTILITY OF THE BAVENO VII CRITERIA FOR A CLINICALLY SIGNIFICANT DECREASE IN LIVER STIFFNESS MEASUREMENT AFTER HCV-CURE
PROGNOSTIC UTILITY OF THE BAVENO VII CRITERIA FOR A CLINICALLY SIGNIFICANT DECREASE IN LIVER STIFFNESS MEASUREMENT AFTER HCV-CURE

Mattias Mandorfer  et al.

THE RISKS OF FIRST HEPATIC DECOMPENSATION AND HCC REMAIN CONSTANT DURING LONG-TERM FOLLOW-UP AND CAN BE STRATIFIED BY A ONE-TIME ASSESSMENT AFTER HCV-CURE
THE RISKS OF FIRST HEPATIC DECOMPENSATION AND HCC REMAIN CONSTANT DURING LONG-TERM FOLLOW-UP AND CAN BE STRATIFIED BY A ONE-TIME ASSESSMENT AFTER HCV-CURE

Mattias Mandorfer  et al.

VALIDATION AND REFINEMENT OF THE BAVENO VII CRITERIA FOR RISK STRATIFICATION IN COMPENSATED ADVANCED CHRONIC LIVER DISEASE AFTER HCV-CURE
VALIDATION AND REFINEMENT OF THE BAVENO VII CRITERIA FOR RISK STRATIFICATION IN COMPENSATED ADVANCED CHRONIC LIVER DISEASE AFTER HCV-CURE

Mattias Mandorfer  et al.

Item 21 - 32 / 32
1
2